- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Maria De Santis presents an overview of managing frail patients with metastatic hormone-sensitive prostate cancer. The presentation explores treatment efficacy data and challenges in frail patients, while emphasizing the importance of supportive interventions and individualized treatment approaches. Biographies: Maria De Santis, MD...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Gerhardt Attard discusses the future landscape of prostate cancer treatments and biomarkers, introducing STAMPEDE2's multi-arm trial design. Dr. Attard also addresses key challenges in radiographic progression-free survival measurements, patient selection, and treatment sequencing. Biographies: Gerhardt Attard, MD, PhD, FRCP, John...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Noel Clarke presents findings from the STAMPEDE trial regarding fracture risk and bone protection in prostate cancer patients. The presentation demonstrates that zoledronic acid reduces fracture incidence by about 50% in metastatic disease, and treatment intensification with abiraterone shows substantial fracture risk reduction, wh...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), a panel discussion explores key questions surrounding androgen deprivation therapy. The experts debate testosterone replacement safety after ADT and the controversy between GnRH agonists and antagonists in cardiovascular outcomes, emphasizing that patient background and risk factor management may influence results more than drug ch...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Ian Davis addresses the complexities of treatment sequencing following doublet therapy for metastatic hormone-sensitive prostate cancer. The presentation explains that treatments like docetaxel, abiraterone, and enzalutamide show greater benefits in hormone-sensitive states than in CRPC, while warning against approaches that might...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Karim Fizazi examines treatment sequencing options following triplet therapy in metastatic castration-sensitive prostate cancer. The presentation emphasizes personalizing treatment based on clinical and biological markers while addressing key scenarios of AR mutations, bypass pathways, and lineage plasticity with neuroendocrine dif...
|
- Details
- Phuoc Tran and Tim Showalter join Zachary Klaassen to discuss two presentations examining the ArteraAI prostate test in oligometastatic castration-sensitive prostate cancer. The conversation explores validation studies demonstrating the test's prognostic value for overall survival and its potential to predict benefit from metastasis-directed therapy using data from the STOMP and ORIOLE trials. The...
|
- Details
- Ursula Vogl discusses key prostate cancer highlights from ESMO 2024. The conversation explores three major trials across different disease stages: the PATCH trial evaluating transdermal estradiol versus LHRH analogs in non-metastatic disease, the ARANOTE trial examining darolutamide in metastatic hormone-sensitive prostate cancer, and the PEACE-3 trial investigating radium-223 plus enzalutamide in...
|
- Details
- Silke Gillessen joins Neeraj Agarwal to discuss the results of the STAMPEDE trial's metformin arm. The phase 3 trial evaluates the addition of metformin to androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer. While the primary endpoint of overall survival is not met, the study reveals significant improvements in metabolic parameters, including reduced w...
|
- Details
- Phillip Koo and Zachary Klaassen discuss the UpFrontPSMA study, a Phase 2 trial published in Lancet Oncology. The study evaluates lutetium-177 PSMA-617 followed by docetaxel versus docetaxel alone in patients with de novo high-volume metastatic hormone-sensitive prostate cancer. They highlight the trial design, which uses PSMA and FDG PET for patient selection, and discuss key results. The primary...
|
